NASDAQ : DNLI
Denali Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 19.32 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.09B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.03B |
| Enterprise Value | 2.13B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 159.85M |
| Shares Outstanding | 159.85M |
| Shares Change (YoY) | +5.80% |
| Shares Change (QoQ) | +0.36% |
| Owned by Insiders (%) | 2.97% |
| Owned by Institutions (%) | 100.15% |
| Float | 155.09M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 840.04 |
| Forward PS | 31.41 |
| PB Ratio | 3.62 |
| P/TBV Ratio | 3.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 589.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.37 |
| Quick Ratio | 7.95 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -54.93% |
| Return on Assets (ROA) | -29.15% |
| Return on Invested Capital (ROIC) | -333.73% |
| Return on Capital Employed (ROCE) | -50.75% |
| Weighted Average Cost of Capital (WACC) | 9.76% |
| Revenue Per Employee | $7,108 |
| Profits Per Employee | -$1.01M |
| Employee Count | 507 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 102,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.02 |
| 52-Week Price Change | +16.55% |
| 50-Day Moving Average | 20.64 |
| 200-Day Moving Average | 21.24 |
| Relative Strength Index (RSI) | 45.28 |
| Average Volume (20 Days) | 1,723,691 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 15.48M |
| Short Previous Month | 15.46M |
| Short % of Shares Out | 9.68% |
| Short % of Float | 9.98% |
| Short Ratio (days to cover) | 7.76 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 3.60M |
| Gross Profit | -397.21M |
| Operating Income | -541.95M |
| Pretax Income | -511.35M |
| Net Income | -511.45M |
| EBITDA | -526.06M |
| EBIT | -541.95M |
| Loss Per Share | -$2.83 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 710.47M |
| Total Debt | 37.69M |
| Net Cash | 902.32M |
| Net Cash Per Share | $5.64 |
| Equity (Book Value) | 835.18M |
| Book Value Per Share | 5.23 |
| Working Capital | 663.84M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -434.04M |
| Capital Expenditures | -3.42M |
| Depreciation & Amortization | 15.89M |
| Net Borrowing | -1.42M |
| Free Cash Flow | -437.46M |
| FCF Per Share | -$2.74 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -15,037.38% |
| Pretax Margin | -14,188.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -5.80% |
| Shareholder Yield | -5.80% |
| Earnings Yield | -14.96% |
| FCF Yield | -14.45% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $35.50 |
| Price Target Difference | 87.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 20 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.45 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |